-
2023
-
Idorsia Urges DEA to Deschedule Chronic Insomnia Drug Class
-
US FDA advisers to weigh full approval for Eisai-Biogen’s Alzheimer’s drug
-
Merck, Eisai decide to discontinue advanced melanoma therapy trial
-
India emerging as world’s leading pharmacy hub
-
Signs of change in Korean diabetes treatment market
-
Caribou’s CAR-T cell therapy receives fast track status
-
Shionogi secures fast track designation for investigational Covid-19 drug
-
Enrollment and Topline Data Expected Sooner for Phase 3 Trial of Pitolisant in Idiopathic Hypersomnia
-
Eisai Presents New Phase 3 Analyses of ARIA and Quality of Life of Lecanemab-Treated Patients
-
Camber Pharmaceuticals Recalls Antifungal Drug Due to Contamination Risk